Hormone replacement therapy: to use or not to use?
- PMID: 12797851
Hormone replacement therapy: to use or not to use?
Abstract
The main indication for hormone replacement therapy (HRT) is to control menopausal symptoms and improve quality of life. Ideally, withdrawal of HRT should be attempted after 4-5 years of therapy. HRT reduces fracture risk and remains appropriate therapy for osteoporosis, particularly in women with symptoms. HRT is not appropriate for primary or secondary cardioprotection. HRT leads to a small increase in breast cancer incidence, which increases with duration of therapy and age. HRT increases the risk of thromboembolism. Patient management and therapy should be reviewed annually with risk-benefit counselling.
Comment in
-
Hormone replacement therapy: to use or not to use?Med J Aust. 2003 Oct 6;179(7):391-2; author reply 392. Med J Aust. 2003. PMID: 14503911 No abstract available.
Similar articles
-
Lessons learned from the WHI: HRT requires a cautious and individualized approach.Geriatrics. 2004 Nov;59(11):22-6. Geriatrics. 2004. PMID: 15615157
-
Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.Climacteric. 2003 May;6 Suppl 1:11-36. Climacteric. 2003. PMID: 12945798 Review.
-
Hormone replacement therapy: what is the evidence today?Z Rheumatol. 2003 Dec;62(6):508-11. doi: 10.1007/s00393-003-0559-y. Z Rheumatol. 2003. PMID: 14685710
-
Justification for the use of HRT in the long-term prevention of osteoporosis.Maturitas. 2005 Jun 16;51(2):113-26. doi: 10.1016/j.maturitas.2005.01.012. Maturitas. 2005. PMID: 15917151 Review.
-
Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study.Menopause. 2003 Sep-Oct;10(5):412-9. doi: 10.1097/01.GME.0000086467.82759.DA. Menopause. 2003. PMID: 14501602
Cited by
-
Therapy for menopausal symptoms during and after treatment for breast cancer : safety considerations.Drug Saf. 2005;28(12):1085-100. doi: 10.2165/00002018-200528120-00004. Drug Saf. 2005. PMID: 16329712 Review.
-
Effects of Polygonatum sibiricum polysaccharide on the osteogenic differentiation of bone mesenchymal stem cells in mice.Int J Clin Exp Pathol. 2015 Jun 1;8(6):6169-80. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26261494 Free PMC article.
-
Depressive symptoms as a risk factor for osteoporosis and fractures in older Mexican American women.Osteoporos Int. 2007 Mar;18(3):315-22. doi: 10.1007/s00198-006-0242-7. Epub 2006 Oct 20. Osteoporos Int. 2007. PMID: 17053870
-
The effects of α-zearalanol on the proliferation of bone-marrow-derived mesenchymal stem cells and their differentiation into osteoblasts.J Bone Miner Metab. 2016 Mar;34(2):151-60. doi: 10.1007/s00774-015-0659-1. Epub 2015 May 6. J Bone Miner Metab. 2016. PMID: 25944420
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources